» Articles » PMID: 39508450

Dissecting Immunological Mechanisms Underlying Influenza Viral Nucleoprotein-induced Mucosal Immunity Against Diverse Viral Strains

Abstract

The nucleoprotein (NP) of type A influenza virus (IAV) is highly conserved across all virus strains, making it an attractive candidate antigen for universal vaccines. While various studies have explored NP-induced mucosal immunity, here we interrogated the mechanistic differences between intramuscular (IM) and intranasal (IN) delivery of a recombinant adenovirus carrying NP fused with a bifunctional CD40 ligand. Despite being less effective than IM delivery in inducing systemic cellular immune responses and antibody-dependent cellular cytotoxicity (ADCC), IN immunization elicited superior antigen-specific recall humoral and cellular response in the nasal associated lymphoid tissue (NALT) of the upper respiratory tract, the initial site of immune recognition and elimination of inhaled pathogens. IN vaccination also induced significantly stronger pulmonary T cell responses in the lower respiratory tract than IM vaccination, in particular the CD8 T cells. Moreover, blocking lymphocyte circulation abrogated IM but not IN immunization induced protection, illustrating the critical role of local memory immune response upon viral infection. Notably, the CD40-targeted nasal delivery not only improved the magnitude but also the breadth of protection, including against lethal challenge with a newly isolated highly pathogenic avian H5N1 strain. These findings are informative for the design of universal mucosal vaccines, where the predominant mode of protection is independent of neutralizing antibodies.

Citing Articles

Adenoviral-Vectored Multivalent Vaccine Provides Durable Protection Against Influenza B Viruses from Victoria-like and Yamagata-like Lineages.

Pekarek M, Madapong A, Wiggins J, Weaver E Int J Mol Sci. 2025; 26(4).

PMID: 40004004 PMC: 11855595. DOI: 10.3390/ijms26041538.

References
1.
Muralidharan A, Russell M, Larocque L, Gravel C, Li C, Chen W . Targeting CD40 enhances antibody- and CD8-mediated protection against respiratory syncytial virus infection. Sci Rep. 2018; 8(1):16648. PMC: 6226510. DOI: 10.1038/s41598-018-34999-z. View

2.
Croyle M, Patel A, Tran K, Gray M, Zhang Y, Strong J . Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One. 2008; 3(10):e3548. PMC: 2569416. DOI: 10.1371/journal.pone.0003548. View

3.
Garigliany M, Habyarimana A, Lambrecht B, Van de Paar E, Cornet A, van den Berg T . Influenza A strain-dependent pathogenesis in fatal H1N1 and H5N1 subtype infections of mice. Emerg Infect Dis. 2010; 16(4):595-603. PMC: 3321946. DOI: 10.3201/eid1604.091061. View

4.
Kornuta C, Langellotti C, Bidart J, Soria I, Quattrocchi V, Gammella M . A plasmid encoding the extracellular domain of CD40 ligand and Montanide™ GEL01 as adjuvants enhance the immunogenicity and the protection induced by a DNA vaccine against BoHV-1. Vaccine. 2021; 39(6):1007-1017. DOI: 10.1016/j.vaccine.2020.11.071. View

5.
Madhavan M, Ritchie A, Aboagye J, Jenkin D, Provstgaad-Morys S, Tarbet I . Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial. EBioMedicine. 2022; 85:104298. PMC: 9550199. DOI: 10.1016/j.ebiom.2022.104298. View